Oppenheimer began coverage on shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) in a research note published on Wednesday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $16.00 price objective on the biopharmaceutical company's stock.
ABEO has been the topic of several other reports. StockNews.com lowered Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 22nd. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $17.50.
Check Out Our Latest Stock Report on ABEO
Abeona Therapeutics Trading Down 2.6 %
Shares of NASDAQ ABEO traded down $0.14 during midday trading on Wednesday, hitting $5.16. The stock had a trading volume of 560,707 shares, compared to its average volume of 303,191. The company has a market capitalization of $224.31 million, a price-to-earnings ratio of -1.92 and a beta of 1.79. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $8.87. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The company has a fifty day moving average price of $5.56 and a 200 day moving average price of $5.85.
Hedge Funds Weigh In On Abeona Therapeutics
Institutional investors have recently made changes to their positions in the business. Twinbeech Capital LP acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at approximately $58,000. Squarepoint Ops LLC acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at approximately $67,000. Jane Street Group LLC acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at approximately $84,000. Oxford Asset Management LLP acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at approximately $118,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at approximately $151,000. 80.56% of the stock is owned by institutional investors and hedge funds.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Articles
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
